Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GEMCAD (Grupo Español Multidisciplinar en Cáncer Digestivo) is a Spanish non-profit cooperative group dedicated to clinical and translational research in digestive system tumors. Founded in 2006, the organization functions as an Academic Research Organization (ARO) that brings together multidisciplinary specialists, including medical oncologists, surgeons, and pathologists, to design and execute clinical trials. GEMCAD focuses on improving treatment outcomes for gastrointestinal cancers through the evaluation of novel therapeutic combinations, including immunotherapies and targeted agents. The group collaborates extensively with the pharmaceutical industry and international research networks to advance clinical guidelines and standard-of-care protocols for colorectal, gastric, and pancreatic malignancies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Grupo Cooperativo GEMCAD.